BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9737681)

  • 1. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
    Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
    Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
    Ramakers-van Woerden NL; Beverloo HB; Veerman AJ; Camitta BM; Loonen AH; van Wering ER; Slater RM; Harbott J; den Boer ML; Ludwig WD; Haas OA; Janka-Schaub GE; Pieters R
    Leukemia; 2004 Mar; 18(3):521-9. PubMed ID: 14712291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
    Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
    Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
    Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
    Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
    Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
    Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.
    Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
    Leuk Lymphoma; 1995 Nov; 19(5-6):407-16. PubMed ID: 8590840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia.
    Kaspers GL; Veerman AJ; Pieters R; van Zantwijk I; Klumper E; Hählen K; de Waal FC; van Wering ER
    Leukemia; 1994 Jan; 8(1):24-9. PubMed ID: 8289494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.
    Pieters R; Loonen AH; Huismans DR; Broekema GJ; Dirven MW; Heyenbrok MW; Hählen K; Veerman AJ
    Blood; 1990 Dec; 76(11):2327-36. PubMed ID: 2257305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia.
    Pieters R; Hongo T; Loonen AH; Huismans DR; Broxterman HJ; Hählen K; Veerman AJ
    Br J Cancer; 1992 May; 65(5):691-7. PubMed ID: 1350207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.
    Den Boer ML; Kapaun P; Pieters R; Kazemier KM; Janka-Schaub GE; Veerman AJ
    Br J Haematol; 1999 Jun; 105(4):876-82. PubMed ID: 10554796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
    Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
    Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
    Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
    Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
    Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R
    Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of 5'-nucleotidase and phosphatase activities with immunophenotype, drug resistance and clinical prognosis in childhood leukemia.
    Pieters R; Huismans DR; Loonen AH; Peters GJ; Hählen K; van der Does-van den Berg A; van Wering ER; Veerman AJ
    Leuk Res; 1992 Sep; 16(9):873-80. PubMed ID: 1405718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
    Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
    Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol.
    Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D
    Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
    Klumper E; Pieters R; Veerman AJ; Huismans DR; Loonen AH; Hählen K; Kaspers GJ; van Wering ER; Hartmann R; Henze G
    Blood; 1995 Nov; 86(10):3861-8. PubMed ID: 7579354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
    Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
    Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.